IBS Subgroups For Lotronex Need Better Definition, Advisory Cmte. Says
Executive Summary
The subgroup of irritable bowel syndrome patients for whom GlaxoSmithKline's Lotronex is most effective needs better definition, members of a joint FDA advisory committee meeting suggested
You may also be interested in...
GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market
GSK Plans Lotronex Randomized Withdrawal Study If Drug Is Reintroduced
GlaxoSmithKline has committed to a randomized withdrawal study for Lotronex if the irritable bowel syndrome agent is allowed back onto the market
Lotronex Prescribing Physicians Must Certify Completion Of CME Program
Physicians prescribing GlaxoSmithKline's Lotronex must first pass a test certifying completion of a special education program, a joint advisory panel recommended April 23